| Literature DB >> 30978561 |
Hongyan Liu1, Danwen Sun2, Hang Du1, Changji Zheng1, Jingya Li3, Huri Piao4, Jia Li5, Liangpeng Sun6.
Abstract
Several series of novel tryptophan-derived rhodanine derivatives were synthesized and identified as potential competitive PTP1B inhibitors and antibacterial agents. Among the compounds studied, 10b was found to have the best in vitro inhibition activity against PTP1B (IC50 = 0.36 ± 0.02 μM). In addition, the compounds also showed potent inhibition against other PTPs, especially CDC25B. Molecular docking analysis demonstrated that compounds 7c and 10b could occupy both the catalytic site and the adjacent pTyr binding site simultaneously. The compounds also showed higher levels of activity against gram-positive strains, the gram-negative strain Escherichia coli 1924, and multidrug-resistant gram-positive bacterial strains. Compounds 7c, 8c, 9e, 10a, and 10c had comparable or more potent antibacterial activity than the positive controls.Entities:
Keywords: Anti-bacterial; PTP1B inhibitor; SAR; Tryptophan-derived rhodanine
Mesh:
Substances:
Year: 2019 PMID: 30978561 DOI: 10.1016/j.ejmech.2019.03.059
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514